Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease

Jihad Mallat, MD, MSc, Fadi Hamed, MD, Maher Balkis, MD, Mohamed A. Mohamed, MD, Mohamad Mooty, MD, Asim Malik, MD, Ahmad Nusair, MD, Maria-Fernanda Bonilla, MD

Abstract
There are conflicting data regarding the use of hydroxychloroquine (HCQ) in COVID-19 hospitalized patients. The objective of this study was to assess the efficacy of HCQ in increasing SARS-CoV-2 viral clearance.

Hospitized adult patients with confirmed SARS-CoV-2 infection were retrospectively included in the study. The primary outcome was the time from a confirmed positive nasopharyngeal swab to turn negative. A negative nasopharyngeal swab conversion was defined as a confirmed SARS-CoV-2 case followed by 2 negative results using RT-PCR assay with samples obtained 24 hours apart. Multiple linear regression analysis was used to adjust for potential confounders.

Thirty-four confirmed COVID-19 patients completed the study. Nineteen (55.9%) patients presented with symptoms, and 14 (41.2%) had pneumonia. Only 21 (61.8%) patients received HCQ. The time to SARS-CoV-2 negativity nasopharyngeal test was significantly longer in patients who received HCQ than those who did not receive HCQ [17 (13–21) vs 10 (4–13) days, P = .023]. HCQ was independently associated with time to negativity test after adjustment for potential confounders (symptoms, comorbidities, antiviral drugs, pneumonia, or oxygen therapy) in multivariable Cox proportional hazards regression analysis (hazard ratio = 0.33, 95% confidence interval: 0.13–0.9, P = .024). On day 14, 47.8% (14/23) patients tested negative in the HCQ group compared with 90.9% (10/11) patients who did not receive HCQ (P = .016).

HCQ was associated with a slower viral clearance in COVID-19 patients with mild to moderate disease. Data from ongoing randomized clinical trials with HCQ should provide a definitive answer regarding the efficacy and safety of this treatment.

Abbreviations: HCQ = hydroxychloroquine, RT-PCR = real-time reverse-transcriptase–polymerase chain reaction.

Keywords: COVID-19 infection, hydroxychloroquine, time to COVID test negativity, viral clearance

1. Introduction
Since December 2019, a novel coronavirus SARS-CoV-2 emerged in Wuhan city and rapidly spread throughout China.[1] Since then, the virus has extended around the world, crossing the Middle East and North Africa region, to Europe and then currently to North America, which has become the epicenter of the pandemic. As of April 19, 2020, a total of around 2,241,778 confirmed cases have been documented globally, with more than 152,551 deaths worldwide.[2]

Therefore, the focus of therapeutic intervention has been to decrease the duration of viral shedding and thus limit the spread of the virus, and slow the progression of the disease. Besides antiviral drugs, chloroquine and hydroxychloroquine (antimalarial drugs) have been proposed as potential agents that could reduce the viral load and the transmission of the virus. Chloroquine analogs appear to block viral entry to cells by inhibiting the acidification of endosomes and glycosylation of host receptors.[3–5] Hydroxychloroquine (HCQ) has been demonstrated to be effective in inhibiting SARS-CoV-2 infection in vitro studies.[6–7]

Clinical studies have shown conflicting results. French studies suggested that HCQ, mainly when used with azithromycin, could reduce the viral load and improve the outcome of patients infected with SARS-CoV-2.[8–9] On the basis of these results, HCQ has been prescribed off-label widely to improve the evolution of these patients. Even an international Task Force led by the American Thoracic Society suggests HCQ on a case-by-case basis for hospitalized patients with COVID-19 who have evidence of pneumonia.[10] However, the efficacy of HCQ in increasing viral clearance has been challenged in recent studies.[11,12] In addition, HCQ can induce QTc prolongation that could result in potentially severe cardiac dysrhythmia. Thus,
this medication should not be used if it is not clinically proven as beneficial, in particular in COVID-19 patients with mild to moderate illness.

The aim of our study was to investigate the efficacy of early use of HCQ in increasing the viral clearance in confirmed hospitalized COVID-19 patients with mild to moderate disease.

2. Materials and methods

2.1. Patients

This was a retrospective observational study performed at Cleveland Clinic Abu Dhabi. The institutional Ethics Committee of Cleveland Clinic Abu Dhabi approved the study, and a waiver of informed consent was obtained due to the nature of the retrospective chart review. All consecutive adult patients (≥18 years) admitted to our hospital between March 1 and 25, 2020, with confirmed SARS-CoV-2 infection were included. A confirmed case of SARS-CoV-2 was defined as a positive result of real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab according to the WHO guidance.[13]

2.2. Data collection

Deidentified data form the electronic medical record was collected. We obtained demographic data, information on clinical symptoms at presentation, and laboratory and radiological results during hospitalization. Imaging was reviewed by a specialized radiologist. C-reactive protein, ferritin level, white blood cells, neutrophil, and lymphocytes counts were also collected around day 7 or at hospital discharge if the latter occurred before. Severe pneumonia was defined as the presence of pneumonia with the need for supplemental oxygen.[13] Mild and moderate diseases were defined according to the WHO criteria.[13] Time from hospital admission to onset pneumonia was also collected. The use of HCQ, lopinavir/ritonavir, Favipiravir was collected. The time from hospital admission to its administration were obtained. According to the hospital protocol, HCQ 400mg was administered twice daily for 1 day, followed by 400mg daily for 10 days. The decision of HCQ and antiviral administrations was left to the Infectious Disease Physician’s discretion.

A negative nasopharyngeal swab conversion was defined as a confirmed SARS-CoV-2 case followed by 2 negative results using RT-PCR assay with samples obtained 24 hours apart. Time to SARS-CoV-2 negativity test, which was our primary outcome, was calculated as the difference between the date of a second confirmed negative result and the date of the first confirmed positive test.

2.3. Statistical analyses

No statistical sample size calculation was performed a priori, and the sample size was equal to the number of patients treated during the study period. Continuous variables are expressed as median and interquartile range (25–75%). Proportions are used as descriptive statistics for categorical variables. Comparisons of values between groups were performed using a Mann–Whitney U test. Pairwise comparisons between the different study periods were assessed using Wilcoxon test. Analyses of discrete data were performed using Chi-square test or Fisher exact test as appropriate.

Time to negativity of COVID-19 test was analyzed using the Kaplan–Meier method, and Log-rank test was used to compare outcomes of patients who received HCQ and those who did not receive the drug. Adjusted Cox proportional hazards regression models were fitted to estimate the association between HCQ and time to negativity test, using clinically likely confounding variable including symptoms, antiviral treatment, comorbidities, the presence of pneumonia, or oxygen therapy. Proportionality hazard assumption was assessed by examining the Cox models to include time-dependent covariates. If the coefficient of the time-dependent covariate was statistically significant, the proportionality hazard assumption would be considered to be violated. A bootstrap method with 1000 sampling with replacement was used to determine the 95% confidence intervals (95% CIs) of regression coefficients parameters by the bias-corrected and accelerated bootstrap method.[14]

Statistical analyses were performed using SPSS software version 24.0 (IBM Corporation, Armonk, NY, USA). P < .05 was considered statistically significant. All reported P values were 2-sided.

3. Results

Thirty-four confirmed COVID-19 patients were enrolled. Among them, only 21 (61.8%) patients received HCQ. The median time from hospital admission to HCQ administration was 0 (0–2) days. The clinical characteristics of the patients are shown in Table 1. The median age was 37 (31–48) years, and 73% were male. Comorbidities were found in 10 cases (29%) with essential hypertension being the most common. The median time from onset of symptoms to hospital admission was 4 days. The most common symptom on admission was cough (50%). Fever was present in only 23% of patients. Fourteen patients developed pneumonia. Among them, 6 (43%) patients required oxygen inhalation with a nasal cannula [2.5 (2.0–4.0) L/min]. The median time from hospital admission to pneumonia was 1.0 (0.0–3.0) days (Table 1). No patients were admitted to intensive care unit, required high flow oxygen therapy, noninvasive or invasive mechanical ventilation, and all of them were discharged alive from the hospital.

No significant differences were found in subject characteristics, symptoms rate, laboratory data, pneumonia rate, or oxygen therapy between HCQ and non-HCQ patients except for comorbidities rate and D-dimer levels, which were significantly higher in the non-HCQ group (Table 1). Twelve (52%) patients received Lopinavir/ritonavir in the HCQ group compared with 3 (27%) in the non-HCQ group. However, this difference was not statistically significant (P = .27). Also, there was no significant difference between patients who received Favipiravir in the HCQ group and the non-HCQ group (22% vs 34%, P = .11, respectively) (Table 1). The hospital length of stay was longer in the HCQ group than in the non-HCQ group, but it did not reach statistical significance [17 (6–20) vs 9 (6–13) days, P = .07, respectively]. HCQ was well tolerated with no observed side effects.

3.1. Factors associated with time to negativity test

The time to SARS-CoV-2 negativity test was significantly longer in patients who received HCQ than those who did not receive the treatment [17 (13–21) vs 10 (4–13) days, P = .023]. The time to negativity test was not significantly different between patients
Table 1
Comparisons of baseline characteristics and laboratory data between HCQ and non-HCQ groups.

| Variables                        | All patients (n = 34) | HCO (n = 23) | Non-HCQ (n = 11) | P   |
|----------------------------------|----------------------|--------------|------------------|-----|
| Age, yr                          | 37 [21–48]           | 33 [21–48]   | 41 [30–55]       | .64 |
| Mule, n (%)                      | 25 (73)              | 17 (74)      | 8 (73)           | 1.00|
| Weight, kg                       | 73 [65–83]           | 73 [64–82]   | 75 [65–92]       | .36 |
| BMI, kg/m²                       | 24.4 [22.7–27.5]     | 24.2 [21.2–26.6] | 24.9 [23.5–30.6] | .38 |
| Symptoms distributions on hospital admission, n (%) | | | | |
| Patients with comorbidities, n (%) | 10 (29)              | 4 (17)       | 6 (54)           | .045|
| Clinical presentation according to WHO criteria, n (%) | | | | |
| Asthma                           | 3 (9)                | 2 (9)        | 1 (9)            |     |
| Diabetes                         | 2 (6)                | 0 (0)        | 2 (18)           |     |
| Hypertension                     | 5 (15)               | 0 (0)        | 5 (45)           |     |
| Malignancy                       | 3 (9)                | 2 (8.7)      | 1 (9)            |     |
| Chronic heart failure            | 1 (3)                | 0 (0)        | 1 (9)            |     |
| Chronic kidney disease           | 1 (3)                | 0 (0)        | 1 (9)            |     |
| Immunosuppressive treatment      | 1 (3)                | 1 (4.3)      | 0 (0)            |     |
| Current tobacco smoker           | 0 (0)                | 1 (4)        | 2 (18)           |     |
| Nonsteroidal anti-inflammatory treatment, n (%) | | | | |
| Fluvoxamine, n (%)               | 4 (12)               | 3 (13)       | 1 (9)            | 1.00|
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Laboratory data on hospital admission, n (%) | | | | |
| Fever                            | 8 (23)               | 6 (26)       | 2 (18)           |     |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Symptoms distributions on hospital admission, n (%) | | | | |
| Fever                            | 8 (23)               | 6 (26)       | 2 (18)           |     |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Laboratory data on hospital admission, n (%) | | | | |
| Fever                            | 8 (23)               | 6 (26)       | 2 (18)           |     |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Patients with symptoms on hospital admission, n (%) | | | | |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Laboratory data on hospital admission, n (%) | | | | |
| Fever                            | 8 (23)               | 6 (26)       | 2 (18)           |     |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Patients with symptoms on hospital admission, n (%) | | | | |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Laboratory data on hospital admission, n (%) | | | | |
| Fever                            | 8 (23)               | 6 (26)       | 2 (18)           |     |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Patients with symptoms on hospital admission, n (%) | | | | |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Laboratory data on hospital admission, n (%) | | | | |
| Fever                            | 8 (23)               | 6 (26)       | 2 (18)           |     |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |
| Patients with symptoms on hospital admission, n (%) | | | | |
| Duration of symptoms before admission, day | 4.0 [2.0–7.0]      | 4.0 [2.0–7.0] | 4.5 [1.2–6.5]    | .65 |

Data are reported as median [interquartile] or count (percentage).

**BMI** = body mass index, **HCQ** = hydroxychloroquine, **WHO** = World Health Organization.

*Means: temperature > 38 degree Celsius.
with symptoms and without symptoms [14 (7–21) vs 15 (4–21) days, respectively, \( P = 1.00 \)], patients who had pneumonia and those who had not [16 (12–21) vs 13 (4–20) days, respectively, \( P = .22 \)], and patients who required oxygen therapy and those who did not [14 (9.2–21) vs 14 (4.5–21) days, respectively, \( P = .84 \)].

Figure 1 shows that HCQ was associated with longer time to COVID-19 test negativity (HR = 0.34 [95% CI: 0.15–0.76], \( p = .009 \)). Table 2 summarizes the results of the univariate and multivariable Cox regression analyses. No variables were significantly associated with the time to negativity test except for HCQ treatment in the simple Cox regression analysis. After adjusting for these potential confounders: symptoms, pneumonia, comorbidities, Lopinavir/ritonavir, and Favipiravir (Table 2) or oxygen therapy (Supplemental digital content: Table 1S, http://links.lww.com/MD/F406), HCQ treatment was independently associated with a longer time to negativity test [hazard ratio (HR) = 0.33, 95% CI: 0.13–0.90, \( P = .024 \)]. The proportionality of HR assumption was met. For the reason of collinearity between oxygen therapy and pneumonia \( (P < .001) \), these variables were not included together in the same multivariable model.

On day 14, only 11 patients among the 23 patients treated with HCQ had their SARS-CoV-2 tests turned negative compared with 10 patients among the 11 patients who did not receive HCQ treatment (47.8% vs 90.9%, respectively, \( P = .016 \)).

![Figure 1. Kaplan–Meier estimates of cumulative negative COVID-19 test proportion.](image)

| **Table 2** |
| Simple and multivariable Cox proportional hazard regression analyses with time to negativity as a dependent variable. |
| --- |
| **Variables** | **Simple Cox regression analysis** | **Multivariable Cox regression analysis** |
|  | Hazard ratio | 95% CI | \( P \) | Hazard ratio | 95% CI | \( P \) |
| HCQ (reference: no) | 0.34 | 0.15–0.76 | .009 | 0.33 | 0.13–0.90 | .024 |
| Symptoms (reference: no) | 0.82 | 0.41–1.66 | .85 | 0.75 | 0.34–1.77 | .49 |
| Pneumonia (reference: no) | 1.00 | 0.48–2.02 | .98 | 1.45 | 0.60–3.53 | .41 |
| Lopinavir/ritonavir (reference: no) | 0.81 | 0.40–1.61 | .54 | 0.64 | 0.25–1.61 | .34 |
| Favipiravir (reference: no) | 0.80 | 0.38–1.71 | .57 | 0.45 | 0.19–1.07 | .07 |
| Comorbidities (reference: no) | 2.18 | 0.98–4.87 | .056 | 3.00 | 1.02–8.85 | .046 |

CI = confidence interval, HCQ = hydroxychloroquine.
Ferritin, m/C20 received HCQ (90.9% vs 47.8%, respectively). The studies HCQ tested negative on day 14 compared with those who significantly higher percentage of our patients who did not receive HCQ (n = 23) Non-HCQ (n = 11)

**Table 3**

Time course of inflammatory variables between admission and day 7 or hospital discharge in the HCQ and non-HCQ groups.

| Variables               | On admission | On day seven or discharge | On admission | On day 7 or discharge |
|-------------------------|--------------|---------------------------|--------------|-----------------------|
| Leucocytes count, /mm³  | 6170 [3620–6520] | 5280 [4427–6445] | 5920 [5160–7470] | 6930 [5640–7430] |
| Lymphocytes count, /mm³ | 1650 [980–1950]  | 1880 [1165–2035] | 1890 [1430–2230] | 1870 [1115–2029] |
| Lymphocytes ≤ 1500/mm³, n (%) | 9 (9.1) | 3.2 (40) | 4 (36.4) | 4.4 (40) |
| Neutrophil/lymphocyte ratio | 2.03 [1.42–2.78] | 1.78 [1.03–3.03] | 2.50 [1.20–2.92] | 1.95 [1.00–4.07] |
| C-reactive protein, mg/L | 3.4 [0.7–7.7] | 2.1 [0.7–4.3] | 4.3 [1.6–16.6] | 4.8 [1.6–53.0] |
| Ferritin, µg/L (reference range: 36–480) | 165 [63–323] | 240 [130–614] | 292 [33–1085] | 398 [52–1030] |

Data are reported as median [interquartile range] or count (percentage). All comparisons were not statistically significant (P > .05).

HCQ = hydroxychloroquine.

### 3.2. Effects of HCQ treatment on the time course of inflammatory markers

Table 3 summarizes that leucocytes counts, lymphocytes counts, lymphopenia rate, C-reactive protein, and ferritin did not significantly change between hospital admission and day seven or hospital discharge in the HCQ group nor the non-HCQ group.

### 4. Discussion

The main findings of our study can be summarized as follows. First, HCQ treatment was independently associated with a longer time to SARS-CoV-2 test negativity. Second, at day 14, virologic clearance was significantly higher in patients who did not receive HCQ. Third, HCQ treatment did not result in improvement of lymphopenia rate (Table 3).

HCQ has been widely used in the prevention and treatment of malaria and the treatment of chronic inflammatory diseases.[15,16] In vitro studies have demonstrated that HCQ exhibits a nonspecific antiviral activity and can block SARS-CoV-2 entry to cells through inhibiting the acidification of endosomes, which prevents membrane fusion and endocytosis of CoV-2 entry to cells through inhibiting the acidification of endosomes, which prevents membrane fusion and endocytosis of the viral envelop.[16,17] In a recent open-label nonrandomized study of 36 patients, Gauthret et al.[8,9] reported improved virologic clearance with HCQ compared with control patients receiving standard supportive care. Virologic clearance, measured by nasopharyngeal swabs, at day 6 was 57% (8/14) for patients who received HCQ monotherapy for 10 days compared with 12.5% (2/16) for patients who did not receive HCQ. In a recent study,[9] the same authors, in a cohort of 80 confirmed COVID-19 patients with mild illness, observed that the combination of HCQ and azithromycin for 10 days resulted in reduced nasopharyngeal viral load (83% and 93% tested negative on days 7 and 8, respectively). Our findings stand in contrast with those reported by Gauthret et al.[8,9] and cast doubt about the strong antiviral efficacy of HCQ. Indeed, we observed that HCQ was independently associated with a longer time for a positive nasopharyngeal swab to turn negative after adjustment for potential confounders (Table 2 and 1S, http://links.lww.com/MDF/F406), suggesting a slower viral clearance. Furthermore, a significantly higher percentage of our patients who did not receive HCQ tested negative on day 14 compared with those who received HCQ (90.9% vs 47.8%, respectively). The studies reported by Gauthret et al.[8,9] had major limitations. In the first study,[8] 6 (23%) patients in the HCQ group were removed from the analysis due to early cessation of treatment resulting from critical illness (transfer to ICU) or intolerance of the drugs. Also, no safety or clinical outcome was reported. The second study[9] had no control arm. Our findings are partly in line with other studies that found no effects of HCQ on viral clearance.[11,12,17]

In a prospective study of 30 COVID-19 patients,[11] the authors randomized patients to HCQ (400 mg daily for 5 days) and standard of care or standard care alone. They found no significant difference in the rate of virologic clearance at day 7 between patients with or without HCQ treatment (86.7% vs 93.3%, respectively), and no difference in clinical outcomes. Molina et al.[17] in patients who received HCQ for 10 days and azithromycin for 5 days, found that 80% (8/10) of them were still positive for SARS-CoV-2 in nasopharyngeal swabs 5 to 6 days after treatment initiation. In a recent multicenter, open-label randomized trial (preprint published),[12] 75 patients were assigned to HCQ (for 2–3 weeks) and standard of care, and 75 patients were assigned to standard of care alone (control group). The authors found that the overall 28-day conversion rate (primary outcome) was not significantly different between the two groups (85.4% for HCQ group vs 81.3% for control group). Also, the time to SARS-CoV-2 negativity test was not significantly different between HCQ and control groups (median 8 vs 7 days, respectively). In a recent retrospective observational study,[16] that included 1376 patients, among them 811 patients received HCQ (600mg twice on day 1, then 400 mg daily for a median of 5 days), the authors found that HCQ administration was not significantly associated with the risk of intubation or death.

Our study is the first to report a slower viral clearance with HCQ use in COVID-19 patients. Although there are no animal studies of chloroquine/HCQ in SARS-CoV-2 infection, data from other viral infections sometimes showed a deleterious effect on viral replication.[19–21] Chloroquine was shown to enhance alphavirus replication in various animal models,[20,21] most probably because of the immune modulation and the anti-inflammatory effects of chloroquine in vivo.[22] Also, in a prophylactic study in a nonhuman primate model of chikungunya virus infection,[19] chloroquine was shown to delay the cellular immune response, resulting in slower viral clearance. Furthermore, in a randomized, double-blind, placebo-controlled trial performed in 83 asymptomatic HIV patients,[21] the use of HCQ compared with placebo resulted in a greater decline in CD4 cell count and increased viral load. Thus, it might be possible that the immunomodulatory effect of HCQ occasioned a slower clearance of the SARS-CoV-19 virus in our patients. However, this finding needs to be confirmed in further studies.

It has been reported that HCQ inhibits SARS-CoV-2 activity in vitro with a half-maximal effective concentration (EC₅₀) ranging from 4.5 to 17 µM,[17] or 150.7 to 5695 µg/L, as the molar mass of HCQ is around 335 g/mole. Considering the blood volume of...
distribution of HCQ of 47.257L,[14] 71240 mg of HCQ would be needed to be given (356 tablets of HCQ 200mg) to achieve an EC50 of 4.5 μM (1507.5 μg/L). Thus, it is unlikely that a standard dosing regimen of HCQ used in clinical practice would be able to inhibit viral activity in COVID-19 patients.

The use of HCQ did not result in the improvement of inflammatory parameters or the lymphopenia rate within seven days of admission. This might be explained by the low inflammatory reaction in our patients on admission suggestive of mild illness severity. Tang et al[12] observed a significant decline in C-reactive protein levels in patients treated with HCQ. However, in their study, HCQ was given at much higher doses (1200 mg daily for 3 days, followed by 800 mg daily) than in our study. Even with such high dosing regimen, HCQ was not able to significantly increase the lymphocyte count.[12]

HCQ use was well tolerated in our patients; we did not observe any side effects. This might be attributed to the low dosing regimen used in our study (400 mg daily).

We acknowledge several limitations to our study, including small sample size and those inherent to retrospective designs. However, baseline patients’ characteristics and laboratory data were well balanced between HCQ and non-HCQ groups. Despite multivariable analysis and adjustment for potential confounders, we cannot rule out bias selection or residual confounding. We included patients with mild to moderate illness. Thus, our results cannot be applied to COVID-19 patients with severe disease.

5. Conclusion
Despite a reported antiviral activity against SARS-CoV-2, we found that HCQ was associated with a slower viral clearance in COVID-19 patients with mild to moderate disease. Data from ongoing randomized clinical trials with HCQ should provide a definitive answer regarding the efficacy and safety of this treatment. Until then, the findings of our study suggest caution in using HCQ in hospitalized COVID-19 patients with mild to moderate illness.

Author contributions
Mallat had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acquisition, analysis, or interpretation of data: Mallat, Hamed, Bonilla, Balkis, Mooty, Mohamed, Malik, Nusair.

Concept and design: Mallat, Hamed.

Conceptualization: Jihad Mallat.

Critical revision of the manuscript for important intellectual content: Mallat, Hamed, Bonilla, Balkis, Mooty, Mohamed, Malik, Nusair.

Data curation: Fadi Hamed, Maher Balkis, Mohamed A. Mohamed, Mohamad Mooty, Asim Malik, Ahmad Nusair, Maria-Fernanda Bonilla.

Drafting of the manuscript: Mallat

Formal analysis: Jihad Mallat.

Methodology: Jihad Mallat.

Statistical analysis: Mallat.

Writing – original draft: Jihad Mallat.

Writing – review & editing: Fadi Hamed, Maher Balkis, Mohamed A. Mohamed, Mohamad Mooty, Asim Malik, Ahmad Nusair, Maria-Fernanda Bonilla.

References
[1] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.
[2] World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 90. March April 19, 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200419-sitrep-90-covid-19.pdf?sfsrm=551d476d_4. Accessed April 20, 2020.
[3] Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect 2017;5:e00293.
[4] Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression [published online March 20, 2020]. J Antimicrob Chemother 2020;75:1667–70.
[5] Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;55:105398.
[6] Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.
[7] Lu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16.
[8] Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.
[9] Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Travel Med Infect Dis 2020;34:101663.
[10] Wilson KC, Chotirmall SH, Bai C, et al. COVID-19: an open-label, randomized, controlled trial. Int J Antimicrob Agents 2020;55:105938.
[11] Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 2017;16:411–9.
[12] Ponticelli C, Moroni G. Hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;382:2411–8.
[13] Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155–66.
[14] Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020;50:384.
[15] Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;382:2411–8.
[16] Roques P, Thierville SD, Dupuis-Maguira L, et al. Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection. Viruses 2018;10:268.
[20] Maheshwari RK, Srikantan V, Bhartiya D. Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice. J Virol 1991;65:992–5.

[21] Seth P, Mani H, Singh AK, et al. Acceleration of viral replication and up-regulation of cytokine levels by antimalarials: implications in malaria-endemic areas. Am J Trop Med Hyg 1999;61:180–6.

[22] Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020;177:104762.

[23] Paton NI, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012;308:353–61.